MS Speaks

The upcoming AAN conference will include presentations by Genentech, according to this April 7 press release from Genentech, which contains this about a new MS drug, fenebrutinib:

Genentech is continuing to advance the science in MS and is exploring the investigational medicine fenebrutinib. Data from fenebrutinib, a highly selective, non-covalent, reversible oral BTKi, support its safety profile in several autoimmune diseases and high potency, which is encouraging for the ongoing Phase III studies in RMS and PPMS. Fenebrutinib is a dual inhibitor of both B-cell and myeloid lineage-cell activation, which may offer a novel approach to slowing disease progression by targeting both acute and chronic inflammatory aspects of MS.

BTKi = Bruton Tyrosine Kinase Inhibitor

The entire article:

https://www.gene.com/media/press-releases/14903/2021-04-07/new-genentech-data-at-2021-aan-highlight